NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 /PRNewswire/ -- NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license...
Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
OMAHA, Neb., April 7 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global biotechnology company, announces that it has completed a licensing
option with the Dana-Farber Cancer Institute, Boston, MA with regard to a method known as Cold-PCR. This variation of t...
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
All amounts are in US dollars
QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing
PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies
INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced
that the company has obtained an exclusive license from Merck Eprova AG to
utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in
Versamune(TM)-HPV and other products in development based on the Versamune(TM)
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C
TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur
Pharma") today announced that it licensed the exclusive U.S. marketing rights
for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R)
(carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen
Codexis, Teva in Licensing Agreement Final
REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced
agreement with Teva Pharmaceutical Industries Ltd., to produce an
important publicly-undisclosed generic product, using a proprietary Codexis
biocatalyst. Teva, the largest generic drug manufacturer in the ...
ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
UNION CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX ), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today that it has entered into a license agreement for co-exclusive worldwid...
DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM
Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange:
CRX), today announced that Hungary-based Gedeon Richter Plc. signed a
VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
International Agreement Licenses Seno's Opto-Acoustic Imaging Technology
To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid
in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and
TORONTO and SAN ANTONIO, TX, Nov. ...
Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ --
Debiopharm Group (Debiopharm), a global biopharmaceutical development
specialist that focuses on serious medical conditions and particularly
oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a
Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
Technology expected to aid drug discovery by allowing for the rapid synthesis of molecules using a single reaction
ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq:
SIAL) is pleased to announce that it has signed an exclusive licensing
agreement with the Universi...
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
The antibiotic surgical product may reduce incidence of surgical site infections and reduce post-operative cost and complications
DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ --
Baxter Healthcare Corporation today announced a licensing
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM ) announced today that it has entered into an exclusive licensing
agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global
pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...
ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a
leader in human embryonic stem cell derived products, announced today that
it has entered into an exclusive worldwide technology licensing
with the University of Georgia Research Foundation that will enable the
GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
ANN ARBOR, Mich., June 5 /PRNewswire/ -- Compendia Bioscience today
announced that it has signed a two-year licensing
GlaxoSmithKline (NYSE: GSK ) for Oncomine(TM) Enterprise Edition, a
value-added product extension Compendia's flagship product, Oncomine.
Oncomine Enterprise Ed...
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV ) today announced that it has out-licensed all worldwide
rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the
clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics,...
Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients
NATICK, Mass. and BALTIMORE, April 15 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) and Surgi-Vision, Inc., a privately held
company, today announc...
AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
TUSTIN, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc.
(Amex: ADL ), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty
pharmaceutical company. In combination with its subsidiary Jade
Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
GAITHERSBURG, Md., March 20 /PRNewswire/ -- Lentigen Corporation today
announced an exclusive licensing
agreement with Case Western Reserve
University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy
for glioblastoma, an aggressive type of brain cancer. Under the agreement,
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) announced the licensing
of its pre-clinical program in Hepatitis C focused on the NS5A target (the
"Program") to San-Francisco based Presidio Pharmaceuticals, Inc. Presidio
is a pri...
Corgenix Signs Technology Licensing Agreement With Japanese Government
AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO DIAGNOSTIC
TECHNOLOGY MEASURING SERUM BIO-MARKER FOR CARDIOVASCULAR INFLAMMATION
DENVER, March 18 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation
(OTC Bulletin Board: CONX), a worldwide developer and marketer of
Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
VANCOUVER, March 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,
Inc. (NASDAQ: ANPI , TSX: ANP) announced today that it has entered into a
agreement with privately held Rex Medical, LP ("Rex
Medical") for exclusive worldwide rights to market and distribute the
ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
SACRAMENTO, Calif., March 3 /PRNewswire/ -- ROBODOC, a Curexo
Technology Company, and IBM announced today that they have entered into a
major patent Cross licensing
agreement. The terms of the agreement were not
disclosed by either party.
In addition to its current surgical robotics patents,...
Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich
MUNICH, Germany and ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ --
Sigma-Aldrich(TM) (Nasdaq: SIAL ) and MorphoSys AG (Frankfurt Stock
Exchange: MOR; Prime Stand...
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
PALO ALTO and SANTA ROSA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (Nasdaq: CVTX ) and Medlogics Device Corporation
announced today that the companies have entered into an agreement under
which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent
mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
- New Deal Advances the Company's Groundbreaking Smart Shape Memory Polymer (BIO-SMP(TM)) Commercialization Program -
AACHEN, Germany, Jan. 30 /PRNewswire/ -- mNEMOSCIENCE GmbH, the pioneer
in the design, manufacture and commercialization of innovative,
biocompatible shape memory p...
Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
Proceeds to Fund U.S. Clinical Trials of Trilobal Tissue Heart Valve and Implantation Technologies
IRVINE, Calif., Jan. 28 /PRNewswire/ -- Arbor Surgical Technologies,
Inc., a privately held medical device company, announced today the closing
of a $20 million dollar Serie...
Angiotech and Symphony Medical Announce Licensing Agreement
New Clinical Program Under Development to Improve Outcomes of Coronary Artery Bypass Grafting (CABG) and Cardiac Valve Surgeries
VANCOUVER, BC and LAGUNA HILLS, CA, Jan. 17 /PRNewswire-FirstCall/ -
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) and privately held
Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as
exclusive financial advisor to Faes Farma (Spain) on its recently-completed
commercial partnering of bilastine with the Menarini Group (Italy). Under
the terms of the agreement, Faes has licensed bilastine rights in Europe...
Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as
exclusive financial advisor to NPS Pharmaceuticals on its
recently-completed partnering of Gattex(TM) (teduglutide) with Nycomed.
Under the terms of the agreement, NPS has licensed rights to Gattex outside
North America to...
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
- HGS acquires exclusive rights to develop and commercialize small-molecule IAP inhibitors in oncology -
- Lead compound AEG40826 works synergistically with HGS TRAIL receptor antibodies to enhance anticancer activity of both drugs -
- IAP inhibitors also show prom...
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for the Treatment of Multiple Sclerosis
INDIANAPOLIS and EDMONTON, Alberta, Dec. 17 /PRNewswire-FirstCall/ --
Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today
announced that the two co...
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation
announced today that it has entered into a strategic collaboration with
Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001,
Alba's lead inhibitor of barrier dysfunction in various gastrointestinal
Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals,
Inc. (AMEX: IMM ) announced today that the Company has granted an exclusive
license to BioAlliance Pharma SA (Euronext Paris - ticker code BIO) to
commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in
Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
PARIS, November 12 /PRNewswire/ -- Aureus Pharma, a leading provider of
knowledge management solutions to accelerate discovery in the life sciences
industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY ) has
renewed its license to Aureus' AurSCOPE GPCR, and has also licensed ...
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
CHAPEL HILL, N.C., and VALAIS, Switzerland, Nov. 5 /PRNewswire/ --
Lantibio, Inc. and TRB Chemedica announced today the signing of a licensing
agreement with a subsidiary of Alcon, Inc. (NYSE: ACL ) for the US
development, marketing, and manufacture of a Dry Eye Syndrome product. The
National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
This development places National Stem Cell in the sector for Anti-aging
products and services, presently a $30 Billion Market, and one of the Biggest Marketing Opportunities in the U.S. Today
MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem
Cell Holding, Inc. (O...
BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
PRINCETON, N.J., Oct. 19 /PRNewswire/ -- BioWa, Inc. (BioWa) announced
today that it has entered into a research agreement which provides
GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R)
Technology platform for the development of antibody-dependent cellular
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Deal Includes up to $100MM in License Fees and Potential Milestone Payments
NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals,
Inc. (Nasdaq: KERX ), announced today that it entered into a licensing
agreement with Japan Tobacco Inc. (JT) (TSE: 2914) and Torii Pharmaceutical